AI Article Synopsis
- Tuberculosis subunit vaccines combined with IL-12-encapsulated microspheres aim to release IL-12 over time, enhancing immune response.
- These vaccines target specific proteins (Ag85A and ESAT-6) to stimulate a strong Th1 immune response.
- The combination of IL-12EM and the AS01B adjuvant is more effective in generating lasting Th1 immunity and protection against tuberculosis.
Article Abstract
Tuberculosis subunit vaccines codelivered with interleukin-12 (IL-12)-encapsulated microspheres (IL-12EM) are designed for a sustained release of IL-12 and could induce strong Th1 immune responses specific to Ag85A and ESAT-6. The adjuvant combination of IL-12EM plus AS01B was a more efficient way to induce a sustained Th1 immunity and protection against Mycobacterium tuberculosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1539587 | PMC |
| http://dx.doi.org/10.1128/IAI.01781-05 | DOI Listing |
Publication Analysis
Top Keywords
tuberculosis subunit
8
enhanced immunogenicity
4
immunogenicity protective
4
protective efficacy
4
efficacy interleukin-12-encapsulated
4
interleukin-12-encapsulated microspheres
4
microspheres as01b
4
as01b tuberculosis
4
subunit vaccination
4
vaccination tuberculosis
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!